Clinical Scorecard: Does Preoperative Active Surveillance Elevate the Risk of Negative Pathological Outcomes or Subsequent Treatment for Prostate Cancer Following Radical Prostatectomy?

At a Glance

Key Highlights

• Deferred radical prostatectomy (RP) associated with higher adverse pathological findings.
• No significant survival disadvantage for deferred RP compared to immediate RP.
• Higher rates of disease progression and treatment in active monitoring groups.
• Median follow-up from diagnosis was 5.6 years.
• Deferred RP occurred after a median of 23 months.

Guideline-Based Recommendations

Diagnosis

• Utilize European Association of Urology (EAU) risk groups for classification.

Management

• Consider active surveillance for low- and favorable intermediate-risk prostate cancer.

Monitoring & Follow-up

• Follow-up should include assessment of adverse pathological findings post-RP.

Risks

• Increased likelihood of adverse pathology with deferred RP.

Patient & Prescribing Data

Men aged 40-79 years with histologically confirmed adenocarcinoma.

Deferred RP may lead to more extensive surgery and higher post-RP treatment rates.

Clinical Best Practices

• Adhere to guideline-based eligibility for active surveillance.
• Monitor for adverse pathological findings in patients undergoing deferred RP.

Related Resources & Content

• Study on adverse pathological findings
• Cohort study on recurrence-free survival
• Swedish nationwide investigation
• ProtecT trial findings